BioSpecifics Technologies Corporation to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference

LYNBROOK, N.Y., March 10, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference on Monday, March 14, 2011, at 11:30 a.m. Pacific Time at the Ritz Carlton in Laguna Niguel, California.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.wsw.com/webcast/roth24/bstc/.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its licensee Auxilium markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe. More information about the Company may be found on its website at www.biospecifics.com.

SOURCE BioSpecifics Technologies Corp.